Evotec Se  (EVO)
Other Ticker:  
Price: $9.8300 $-0.13 -1.305%
Day's High: $9.96 Week Perf: 0.51 %
Day's Low: $ 9.79 30 Day Perf: 8.98 %
Volume (M): 22 52 Wk High: $ 13.49
Volume (M$): $ 218 52 Wk Avg: $10.26
Open: $9.92 52 Wk Low: $7.80

 Market Capitalization (Millions $) 1,737
 Shares Outstanding (Millions) 177
 Employees 3,072
 Revenues (TTM) (Millions $) 842
 Net Income (TTM) (Millions $) -197
 Cash Flow (TTM) (Millions $) 783
 Capital Exp. (TTM) (Millions $) 203

Evotec Se
Evotec SE is a publicly-traded German biotechnology firm operating in the pharmaceutical and drug discovery industry. The company is headquartered in Hamburg, Germany, and has various locations and offices worldwide.

Evotec SE is primarily engaged in the development and discovery of drugs, which includes providing comprehensive solutions for the pharmaceutical industry. The company works with leading biopharmaceutical companies, academic institutions, and disease foundations, focusing on providing innovative solutions through collaborations and partnerships.

Founded in 1993, the company has over the years been focused on research and development, cutting-edge technologies and collaboration, drug discovery, and strategic partnerships. The company has built a reputation as a leading provider of high-value drug discovery services, particularly in the fields of neuroscience, oncology, and autoimmune diseases.

Their technology platform, called the "Evotec Operating System," integrates different lab technologies and data management capabilities, enabling high-throughput screening and drug identification. This platform has been instrumental in the company's success as it enables them to work collaboratively and efficiently in the drug discovery process.

Evotec SE's services range from target identification, validation, and optimization to drug screening, hit identification, and preclinical development. The company also offers customized solutions tailored for specific client needs and has several programs in clinical and pre-clinical stages of development.

Additionally, Evotec SE has an extensive drug development pipeline, which includes both proprietary programs as well as partnered programs. To date, the company has over 100 partners across the globe and an impressive portfolio of drug candidates.

In terms of financials, Evotec SE has been consistent in its revenue growth, with a revenue increase of 17% in 2020 compared to the previous year. As of mid-2021, the company reported a total of over 4,000 employees worldwide, showing significant growth and expansion over the years.

Overall, Evotec SE has established itself as a leading biotech company that leverages cutting-edge technologies, strategic partnerships, and collaboration in drug discovery and development. With a proven track record, a robust pipeline, and consistent growth, the company is well-positioned to continue making significant strides in the biotech industry.

   Company Address: Essener Bogen 7 Hamburg 22419
   Company Phone Number: 40 560810   Stock Exchange / Ticker: NASDAQ EVO
   EVO is expected to report next financial results on May 11, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Conduit Pharmaceuticals Inc

Conduit Pharmaceuticals Inc. Records Operating Shortfall in Q3 2023 but Reveals Promising Financial Indicators

As the earnings cycle for the third quarter of 2023 unfolds, various industries are reporting their financial results. One notable sector is Major Pharmaceutical Preparations, with Conduit Pharmaceuticals Inc being among the corporations announcing its numbers. Despite the absence of realized products and services, the company reported an operating shortfall of $-1.069 million during the July to September 30, 2023 period. However, a closer look at the financials reveals positive indicators, including a significant increase in net profits compared to the previous year. This article aims to analyze and contextualize the financial results of Conduit Pharmaceuticals Inc.
Financial Performance and Stakeholder Expectations:
During the current reporting period, Conduit Pharmaceuticals Inc faced an operating shortfall of $-1.069 million. This unfavorable figure, suggesting a loss for the company, signals the need for additional revenue sources to be explored as soon as possible. However, despite the current financial challenges, stakeholders seem less concerned about the organization's operational excellence and recent developments.

Ayala Pharmaceuticals Inc

ADXS Surpasses Expectations with Strong Third Quarter Results, Drives Optimism in the Pharmaceutical Industry

In the Major Pharmaceutical Preparations industry, where large companies dominate the market, smaller players are making their presence felt with promising results. One such company worth noting is ADXS, which recently announced an operating loss of $-7.131 million for the third quarter of 2023?a significant improvement compared to the same period last year, when the loss was $-7.291 million.
ADXS's positive results come as welcome news, particularly given the lack of easier references in the industry. This performance has generated optimism among market observers, who are now eyeing ADXS as a potential investment opportunity. The company's relentless pursuit of diverse corporate strategies aimed at ensuring new revenue streams has further bolstered this confidence.

Anebulo Pharmaceuticals Inc

Anebulo Pharmaceuticals Inc Achieves Promising Improvement, Reporting Operating Loss of $-2.543678 Million in Q1 2024

Anebulo Pharmaceuticals Inc, a lesser-known player in the Major Pharmaceutical Preparations sector, recently published their financial numbers for the first quarter of 2024. In a positive surprise for investors and analysts, the company announced that it had realized an operating loss of -$2.543678 million, an improvement from the previous year's operating loss of -$2.612047 million.
What is particularly noteworthy about this improvement is the decrease in diminishing returns, from -$2.612 million in the first quarter of 2023 to -$2.481 million in the same period this year. This suggests that Anebulo Pharmaceuticals Inc is making progress towards becoming an exceptional company in the Healthcare sector.

Qualigen Therapeutics Inc

Lackluster revenue at the Qualigen Therapeutics Inc in the most recent fiscal period

Qualigen Therapeutics Inc stock has seen some fluctuations in recent trading days. However, over the last five trading days, the stock experienced a solid gain of 7.2%. This positive movement comes after a slight decline of -1.91% during the preceding month.
Investors may also note that Qualigen Therapeutics Inc stock is currently trading only 12.3% above its 52-week low. This suggests that the stock has not seen significant upward momentum in recent months.

Onconova Therapeutics Inc

A deficit of $-0.23 per Share at the Onconova Therapeutics Inc amid the fiscal third quarter of 2023

Onconova Therapeutics Inc (ONTX) has recently reported its fiscal third-quarter results for 2023, and the numbers are not looking promising for the biopharmaceutical company. The company's financials reveal a decrease in earnings per share (EPS) compared to the same quarter last year, as well as a surge in deficit from the previous quarter.
For the fiscal third quarter of 2023, ONTX reported a loss of $-0.23 per share, which is slightly better than the loss of $-0.26 per share reported a year ago. However, compared to the previous quarter, the deficit has increased from $-0.20 per share. This indicates a concerning trend of worsening financial performance for the company.


Evotec Se's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com